figshare
Browse
000319742_sm_supplemental_material.pdf (35.07 kB)

Supplementary Material for: Mitomycin C in Patients with Gynecological Malignancies

Download (35.07 kB)
dataset
posted on 2010-09-06, 00:00 authored by Kahmann L., Beyer U., Mehlhorn G., Thiel F.C., Strnad V., Fasching P.A., Lux M.P.
Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma. This review presents and discusses the current treatment options with MMC in patients with breast, cervical, and vulvar carcinomas, as well as rarer gynecological malignancies. New combinations and developments are also presented and their potential clinical relevance is examined. Consequently, also for the next years a MMC-containing chemotherapy continues to be a relevant part of an individualized therapy despite numerous innovative new drugs, especially for the salvage therapy of metastatic breast cancer and the simultaneous radiochemotherapy of other gynecological malignancies.

History

Usage metrics

    Oncology Research and Treatment

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC